Company news

Kura Oncology, Inc. news in 2021

Kura Oncology, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

December 15, 2021

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

December 12, 2021

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

December 12, 2021

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

November 23, 2021

Kura Oncology Reports Third Quarter 2021 Financial Results

November 3, 2021

Kura Oncology to Participate in Credit Suisse Healthcare Conference

November 1, 2021

Kura Oncology to Report Third Quarter 2021 Financial Results

October 27, 2021

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

October 17, 2021

Kura Oncology Reports Second Quarter 2021 Financial Results

August 4, 2021

Kura Oncology to Report Second Quarter 2021 Financial Results

July 28, 2021

Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

July 28, 2021

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

July 5, 2021

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

June 23, 2021

Kura Oncology to Participate in JMP Securities Life Sciences Conference

June 9, 2021

Kura Oncology Appoints Carol Schafer to Board of Directors

June 3, 2021

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

May 12, 2021

Kura Oncology Reports First Quarter 2021 Financial Results

May 5, 2021

Kura Oncology to Report First Quarter 2021 Financial Results

April 28, 2021

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

March 21, 2021

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

February 23, 2021

Kura Oncology to Participate in Four Upcoming Investor Conferences

February 17, 2021

Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results

February 16, 2021

Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference

January 6, 2021

Kura Oncology to Present at J.P. Morgan Healthcare Conference

January 5, 2021

Calls in 2021

Decks in 2021